Unleashing the Power of Tregs

Multiple Treg therapeutic modalities addressing neurodegenerative, autoimmune, and metabolic diseases

We are a clinical-stage company focused on developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Strong proof of concept data in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s

Treg Enhancing Biologics:

Treg Enhancing
Biologics:

Allogeneic Treg
Derived Exosomes:

Autologous Treg
Cell Therapy:

News

Keep up-to-date with the latest news about Coya Therapeutics.

Coya Therapeutics, Inc. Announces Pricing of $15.25 Million Initial Public Offering

Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Announces Peer-Reviewed Publication of its First- in-Class Regulatory T cell derived Exosomes and Their Therapeutic Potential in Neurodegeneration and Inflammation-Related Diseases

We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. We are currently developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Links

follow us

Contact Us

© 2023 Coya Therapeutics, Inc. All rights reserved.